Decnupaz (pivekimab sunirine) has received U.S. FDA approval for use in adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a very rare and aggressive blood cancer with few effective therapies available. This medicine is an antibody-drug conjugate (ADC) and is notable because treatment can be started in the outpatient setting rather than requiring admission to the hospital. It also represents AbbVie’s first ADC approved in the hematology/oncology space.

The Saudi Food and Drug Authority (SFDA) has granted Novo Nordisk’s therapy, denecimig, designation as a “promising drug.” The therapy is intended for long-term use to prevent or reduce bleeding episodes in patients with hemophilia A across different age groups, regardless of the presence of factor VIII inhibitors. Denecimig, a bispecific antibody belonging to a class of protein-based therapies. It works by binding to two key proteins involved in the blood clotting process,